• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hum Genomics . COVID-19 annual update: a narrative review

tetano

Editor, Senior Moderator
Hum Genomics


. 2023 Jul 24;17(1):68.
doi: 10.1186/s40246-023-00515-2. COVID-19 annual update: a narrative review

Michela Biancolella[SUP] #[/SUP][SUP] 1 [/SUP], Vito Luigi Colona[SUP] #[/SUP][SUP] 2 [/SUP], Lucio Luzzatto[SUP] #[/SUP][SUP] 3 4 [/SUP], Jessica Lee Watt[SUP] 5 [/SUP], Giorgio Mattiuz[SUP] 4 [/SUP], Silvestro G Conticello[SUP] 6 7 [/SUP], Naftali Kaminski[SUP] 8 [/SUP], Ruty Mehrian-Shai[SUP] 9 [/SUP], Albert I Ko[SUP] 10 11 [/SUP], Gregg S Gonsalves[SUP] 12 [/SUP], Vasilis Vasiliou[SUP] 13 [/SUP], Giuseppe Novelli[SUP] #[/SUP][SUP] 14 15 16 [/SUP], Juergen K V Reichardt[SUP] #[/SUP][SUP] 17 [/SUP]



Affiliations
Abstract

Three and a half years after the pandemic outbreak, now that WHO has formally declared that the emergency is over, COVID-19 is still a significant global issue. Here, we focus on recent developments in genetic and genomic research on COVID-19, and we give an outlook on state-of-the-art therapeutical approaches, as the pandemic is gradually transitioning to an endemic situation. The sequencing and characterization of rare alleles in different populations has made it possible to identify numerous genes that affect either susceptibility to COVID-19 or the severity of the disease. These findings provide a beginning to new avenues and pan-ethnic therapeutic approaches, as well as to potential genetic screening protocols. The causative virus, SARS-CoV-2, is still in the spotlight, but novel threatening virus could appear anywhere at any time. Therefore, continued vigilance and further research is warranted. We also note emphatically that to prevent future pandemics and other world-wide health crises, it is imperative to capitalize on what we have learnt from COVID-19: specifically, regarding its origins, the world's response, and insufficient preparedness. This requires unprecedented international collaboration and timely data sharing for the coordination of effective response and the rapid implementation of containment measures.

Keywords: COVID-19; Coronavirus; Pandemic; Public health; SARS-CoV-2; Susceptibility genes; Therapy; Vaccines; Variants.

 
Back
Top Bottom